Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients.

Bryant LM, Daniels KE, Cognetti DM, Tassone P, Luginbuhl AJ, Curry JM.

Laryngoscope Investig Otolaryngol. 2018 Apr 16;3(3):169-177. doi: 10.1002/lio2.154. eCollection 2018 Jun. Review.

2.

Association of Positive Initial Margins With Survival Among Patients With Squamous Cell Carcinoma Treated With Total Laryngectomy.

Tassone P, Savard C, Topf MC, Keane W, Luginbuhl A, Curry J, Cognetti D.

JAMA Otolaryngol Head Neck Surg. 2018 Jul 26. doi: 10.1001/jamaoto.2018.1095. [Epub ahead of print]

PMID:
30054637
3.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Jul 11. pii: blood-2018-03-836601. doi: 10.1182/blood-2018-03-836601. [Epub ahead of print]

PMID:
29997223
4.

Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation.

Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, Tassone P, Amodio N.

Curr Med Chem. 2018 Jun 29. doi: 10.2174/0929867325666180629153141. [Epub ahead of print]

PMID:
29956610
5.

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P.

Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.

6.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P.

J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.

7.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P.

Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.

8.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A.

J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.

9.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Apr 19. pii: haematol.2018.189969. doi: 10.3324/haematol.2018.189969. [Epub ahead of print]

10.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.

PMID:
29650279
11.

Buccal space malignancy in the setting of chronic sialadenitis: A report of 2 cases.

Bryant LM, Tassone P, Curry J, Luginbuhl A, Cognetti D.

Ear Nose Throat J. 2018 Jan-Feb;97(1-2):E12-E14.

PMID:
29493724
12.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0067-3. [Epub ahead of print]

13.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P.

Blood Adv. 2017 Feb 27;1(7):455-466. doi: 10.1182/bloodadvances.2016003905. eCollection 2017 Feb 28.

14.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

15.

Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.

Franzoni S, Vezzelli A, Turtoro A, Solazzo L, Greco A, Tassone P, Di Martino MT, Breda M.

J Pharm Biomed Anal. 2018 Feb 20;150:300-307. doi: 10.1016/j.jpba.2017.12.027. Epub 2017 Dec 15.

PMID:
29268195
16.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, Tassone P, Caraglia M.

Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.

17.

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

Raimondi L, De Luca A, Costa V, Amodio N, Carina V, Bellavia D, Tassone P, Pagani S, Fini M, Alessandro R, Giavaresi G.

Oncotarget. 2017 Aug 3;8(59):100831-100851. doi: 10.18632/oncotarget.19852. eCollection 2017 Nov 21. Review.

18.

Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts.

Tassone P, Domingo-Vidal M, Whitaker-Menezes D, Lin Z, Roche M, Tuluc M, Martinez-Outschoorn U, Curry J.

Otolaryngol Head Neck Surg. 2018 May;158(5):867-877. doi: 10.1177/0194599817746934. Epub 2017 Dec 12.

PMID:
29232177
19.

Unplanned readmission following transoral robotic surgery.

Topf MC, Vo A, Tassone P, Shumrick C, Luginbuhl A, Cognetti DM, Curry JM.

Oral Oncol. 2017 Dec;75:127-132. doi: 10.1016/j.oraloncology.2017.11.009. Epub 2017 Nov 11.

PMID:
29224809
20.

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P.

J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.

21.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

22.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

23.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

24.

Naso- or Orbitocutaneous Fistulas after Free Flap Reconstruction of Orbital Exenteration Defects: Retrospective Study, Systematic Review, and Meta-Analysis.

Tassone P, Gill KS, Hsu D, Nyquist G, Krein H, Bilyk JR, Murchison AP, Evans JJ, Heffelfinger RN, Curry JM.

J Neurol Surg B Skull Base. 2017 Aug;78(4):337-345. doi: 10.1055/s-0037-1600135. Epub 2017 Mar 16.

25.

Tumor Metabolism in the Microenvironment of Nodal Metastasis in Oral Squamous Cell Carcinoma.

Curry J, Tassone P, Gill K, Tuluc M, BarAd V, Mollaee M, Whitaker-Menezes D, Rodeck U, Luginbuhl A, Cognetti D, Keane W, Martinez-Outschoorn U.

Otolaryngol Head Neck Surg. 2017 Nov;157(5):798-807. doi: 10.1177/0194599817709224. Epub 2017 Jun 13.

PMID:
28608777
26.

Pathologic Markers in Surgically Treated HPV-Associated Oropharyngeal Cancer: Retrospective Study, Systematic Review, and Meta-analysis.

Tassone P, Crawley M, Bovenzi C, Zhan T, Keane W, Cognetti D, Luginbuhl A, Curry J.

Ann Otol Rhinol Laryngol. 2017 May;126(5):365-374. doi: 10.1177/0003489417693014. Epub 2017 Feb 16.

PMID:
28397563
27.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P.

Curr Cancer Drug Targets. 2017;17(9):819-838. doi: 10.2174/1568009617666170330154756. Review.

PMID:
28359248
28.

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.

Curry J, Johnson J, Tassone P, Vidal MD, Menezes DW, Sprandio J, Mollaee M, Cotzia P, Birbe R, Lin Z, Gill K, Duddy E, Zhan T, Leiby B, Reyzer M, Cognetti D, Luginbuhl A, Tuluc M, Martinez-Outschoorn U.

Laryngoscope. 2017 Aug;127(8):1808-1815. doi: 10.1002/lary.26489. Epub 2017 Feb 10.

29.

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, Tassone P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M.

Leukemia. 2017 Sep;31(9):1894-1904. doi: 10.1038/leu.2016.394. Epub 2017 Jan 5.

PMID:
28053325
30.

Immunotherapy of colorectal cancer: new perspectives after a long path.

Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P.

Immunotherapy. 2016 Nov;8(11):1281-1292. Review.

PMID:
27993089
31.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

Botta C, Di Martino MT, Ciliberto D, Cucè M, Correale P, Rossi M, Tagliaferri P, Tassone P.

Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.

32.

Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.

Amodio N, D'Aquila P, Passarino G, Tassone P, Bellizzi D.

Expert Opin Ther Targets. 2017 Jan;21(1):91-101. Review.

PMID:
27892767
33.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K.

Leukemia. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358. Epub 2016 Nov 28.

PMID:
27890927
34.

TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.

Ko YH, Domingo-Vidal M, Roche M, Lin Z, Whitaker-Menezes D, Seifert E, Capparelli C, Tuluc M, Birbe RC, Tassone P, Curry JM, Navarro-Sabaté À, Manzano A, Bartrons R, Caro J, Martinez-Outschoorn U.

J Biol Chem. 2016 Dec 16;291(51):26291-26303. Epub 2016 Nov 1.

35.

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.

Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P.

Cancer Biol Ther. 2016 Nov;17(11):1213-1220.

36.

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.

Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P.

Oncotarget. 2016 Dec 13;7(50):82741-82756. doi: 10.18632/oncotarget.12633. Review.

37.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P.

Cell Death Discov. 2016 Oct 3;2:16025. eCollection 2016.

38.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P, Cannataro M.

Microarrays (Basel). 2016 Sep 23;5(4). pii: E24. doi: 10.3390/microarrays5040024.

39.

Characterization of the transcription factor encoding gene, KlADR1: metabolic role in Kluyveromyces lactis and expression in Saccharomyces cerevisiae.

Cardarelli S, D'Amici S, Tassone P, Tramonti A, Uccelletti D, Mancini P, Saliola M.

Microbiology. 2016 Nov;162(11):1933-1944. doi: 10.1099/mic.0.000374. Epub 2016 Sep 15.

PMID:
27655407
40.

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.

Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A.

Blood Cancer J. 2016 Sep 9;6(9):e468. doi: 10.1038/bcj.2016.77.

41.

Postoperative cerebrospinal fluid leak after microvascular reconstruction of craniofacial defects with orbital exenteration.

Gill KS, Hsu D, Tassone P, Pluta J, Nyquist G, Krein H, Bilyk J, Murchison AP, Iloreta A, Evans JJ, Heffelfinger RN, Curry JM.

Laryngoscope. 2017 Apr;127(4):835-841. doi: 10.1002/lary.26137. Epub 2016 Sep 7.

PMID:
27601262
42.

Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients.

Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, Chiurazzi F, Fiume G, Pisano A, Ceglia S, Pontoriero M, Golino G, Tassone P, Quinto I, Scala G, Palmieri C.

Leukemia. 2016 Dec;30(12):2419-2422. doi: 10.1038/leu.2016.245. Epub 2016 Aug 29. No abstract available.

43.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P.

Cell Death Dis. 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211. No abstract available.

44.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.

Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT.

Mol Ther Nucleic Acids. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36.

45.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

46.

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, Tassone P, Tagliaferri P, Caraglia M.

Curr Drug Targets. 2017;18(1):35-55. Review.

PMID:
27280795
47.

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L.

Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31. Review. No abstract available.

48.

Thyroid Cancer Metabolism: A Review.

Gill KS, Tassone P, Hamilton J, Hjelm N, Luginbuhl A, Cognetti D, Tuluc M, Martinez-Outschoorn U, Johnson JM, Curry JM.

J Thyroid Disord Ther. 2016 Feb;5(1). pii: 200. Epub 2016 Jan 14.

49.

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A.

J Ovarian Res. 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7.

50.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P.

Mol Cancer Ther. 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985. Epub 2016 May 18.

Supplemental Content

Loading ...
Support Center